Phio Pharmaceuticals Corp. (PHIO) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Per the Roarable RQD rating, PHIO scores 36 out of 100, a letter grade of D-, with the verdict "Roarable Sell — Vulnerable Balance Sheet & Flow." The five pillars are: Fundamental Cash Engine at 7/20 (ROIC -35%; FCF yield 0%), Whale 13F Flow at 4/20 (institutional accumulation and options positioning), Insider Conviction at 5/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit at 10/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 1/9; Debt/Equity 0.5). For a prospective investor, the weakest pillars are the cash engine and the flow signals, which together indicate that the company is not currently generating cash returns and that institutional and insider signals are not supportive. The forensic pillar is the most balanced, with an Altman Z of 2.5 and a Debt/Equity of 0.5, but the Piotroski F-Score of 1 out of 9 signals weak financial health across the nine tests. Upside drivers would need to come from a change in the cash engine, which the source data does not show, and valuation is difficult to assess because P/E and EV/EBITDA are not available in source data. The market is pricing the stock at $0.86 with a market cap of $10.0M, near the bottom of its 52-week range of $0.81 to $4.19.

Phio Pharmaceuticals Corp. is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry, per the profile. The profile describes the company as a Health Care issuer with a market capitalization of $0.0B. Per the news wire, the company's pipeline focus includes a cancer approach designed to help immune cells fight tumors and a skin cancer program. Revenue reported in the SEC financials is $0.0M in each listed period, and the source data does not describe a product sales or monetization model.

Per the SEC financials, the company reported no revenue and operating losses in each period shown. Per the market data, gross, operating, and net margins are each 0%, and ROIC is -35%. The Roarable RQD rating reports an Altman Z-Score of 2.5, a Piotroski F-Score of 1 out of 9, and a Debt/Equity of 0.5. Reported cash rose from $5.4M in FY 2024 to $21.0M in FY 2025, while debt is listed as N/A in every period.

Per the news wire, all six items relate to PHIO and carry a YELLOW light with a MARKET WIRE impact label. The headlines reference an upcoming presentation at The Global Markets Virtual Forum on October 8, 2026, a presentation at the National Investment Banking Association (NIBA) 153rd Conference, a planned Florida talk covering the skin cancer program, an estimates page from TradingView, and a Benzinga after-market mover listing. These are presentation and visibility events rather than reported financial results. The butterfly supply-chain graph reports no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlations beyond the profile classification in Health Care and Biotechnology: Pharmaceutical Preparations. A prospective investor should watch whether the company's cash position of $21.0M in FY 2025 is sufficient to fund continued operating losses of $-9.2M, but the source data does not provide a runway estimate.

• What is the company's cash runway, given the reported FY 2025 cash of $21.0M and operating loss of $-9.2M?
• What are the terms and status of the company's debt, since debt is listed as N/A in every reported period?
• What are the P/E and EV/EBITDA ratios, which are not available in source data given negative earnings?
• What is the company's revenue or collaboration model, given zero reported revenue in all periods?
• What pipeline milestones or regulatory events are scheduled beyond the listed presentations?